Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001 (Q35229978)

7 August 2017

title

Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001 (English)

1 reference

7 August 2017

1 reference

1 reference

9

Hagop Kantarjian

1 reference

7 August 2017

10

Srdan Verstovsek

1 reference

7 August 2017

2

Jorge Cortes

1 reference

7 August 2017

7

Carlos Bueso-Ramos

1 reference

7 August 2017

6

Taghi Manshouri

1 reference

7 August 2017

5

Pat Ault

1 reference

7 August 2017

3

Matjaz Sever

1 reference

7 August 2017

Roberto H Nussenzveig

series ordinal

1

object named as

Roberto H Nussenzveig

1 reference

7 August 2017

8

Josef T Prchal

1 reference

7 August 2017

author name string

Alfonso Quintás-Cardama

series ordinal

4

1 reference

7 August 2017

publication date

30 May 2009

1 reference

International Journal of Hematology

7 August 2017

published in

1 reference

7 August 2017

volume

90

1 reference

7 August 2017

issue

1

1 reference

7 August 2017

page(s)

58-63

1 reference

Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia

7 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Imatinib effect on growth and signal transduction in polycythemia vera

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Identification of an acquired JAK2 mutation in polycythemia vera

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

A gain-of-function mutation of JAK2 in myeloproliferative disorders

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Molecular basis for polycythemia

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Letter: Bone-marrow responses in polycythemia vera

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Phase II open label trial of imatinib in polycythemia rubra vera

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Polycythemia vera is not initiated by JAK2V617F mutation.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Identification of c-Kit gene mutations in patients with polycythemia vera

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Imatinib mesylate in polycythemia vera

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

Polycythemia vera responds to imatinib mesylate

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4378576

JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19484334

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12185-009-0345-Y

1 reference

7 August 2017

1 reference

7 August 2017

1 reference